SCHEMBL9892665

SCHEMBL9892665

CNC(=O)Cc1ccccc1-c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLQ O75417 1/20 0.46
KCNJ5 P48544 1/20 0.44
KCNJ3 P48549 1/20 0.44
HTT P42858 1/20 0.43
ALDH1A1 P00352 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 2/20 0.41
P2RX7 Q99572 2/20 0.41
GAA P10253 3/20 0.40
RORC P51449 1/20 0.40
GRM5 P41594 1/20 0.40
F2 P00734 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
GRIK1 P39086 1/20 0.39
CNR2 P34972 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892682 0.86 P2RX7 (0.42) KCNJ5KCNJ3P2RX7RORC
SCHEMBL2392432 0.85 MEN1 (0.44) POLQKCNJ5KCNJ3HTTALDH1A1
SCHEMBL9890756 0.82 SUCNR1 (0.46) KCNJ5KCNJ3KDM4EGAALMNA
SCHEMBL9892661 0.79 P2RX7 (0.42) KCNJ5KCNJ3ALDH1A1KDM4EP2RX7
SCHEMBL9890749 0.78 P2RX7 (0.46) POLQP2RX7
SCHEMBL8568288 0.76 POLQ (0.55) POLQKCNJ5KCNJ3HTTALDH1A1
SCHEMBL9890748 0.76 CYP11B1 (0.46) KCNJ5KCNJ3HTTKDM4ERORC
SCHEMBL9890714 0.76 CYP2C19 (0.49)
SCHEMBL2395234 0.75 CNR1 (0.43) ALDH1A1P2RX7LMNA
SCHEMBL9890718 0.75 KMT2A (0.49) KCNJ5KCNJ3HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 POLQ 3938/4885KCNJ5 282/4885KCNJ3 260/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 POLQ 3938/4885KCNJ5 282/4885KCNJ3 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.